ZNTL — Zentalis Pharmaceuticals Balance Sheet
0.000.00%
- $104.33m
- -$266.75m
- $67.43m
- 35
- 57
- 20
- 30
Annual balance sheet for Zentalis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 339 | 340 | 437 | 483 | 371 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.417 | 0.004 | 6.38 | 3.34 | 7.94 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 345 | 351 | 452 | 497 | 386 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.62 | 52.8 | 50.1 | 41.7 | 37.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 366 | 455 | 539 | 552 | 430 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 28.6 | 43.9 | 56.6 | 69.4 | 52.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 57 | 90.6 | 106 | 114 | 93.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 309 | 364 | 434 | 437 | 337 |
Total Liabilities & Shareholders' Equity | 366 | 455 | 539 | 552 | 430 |
Total Common Shares Outstanding |